Biography

Abdelbary is a Professor in Pharmaceutics, and the Head of Pharmaceutical Sciences Department at the College of Pharmacy, Qatar University. Professor Elhissi combines a strong expertise in research at both academic and industrial levels. He obtained his PhD in 2005 from UCL School of Pharmacy and then worked as a postdoctoral research Fellow at UCL (2005-2006). He worked in Pharmaceutical Industry at Lipoxen Technologies Ltd, UK as Senior Scientist (2006-2007) with responsibility of developing anticancer nanomedicine formulations. Abdelbary joined the University of Central Lancashire (UCLan) in UK as Lecturer (2007-2011) and Senior Lecturer (2011-2014), where he was the lead of pharmaceutics and established one of the largest drug delivery research groups in UK. He served as Deputy Head and a founding member of the UCLan’s Institute of Nanotechnology and Bioengineering (2011-2014). Abdelbary moved to QU as Associate Professor at the College of Pharmacy in 2014 and was promoted to Professor in 2019. Parallel to this, Abdelbary is the Founding Manager of the Research Excellence Office (2017-2020) and then he served as Director of Research Planning and Development at QU (2020 – 2022). Abdelbary authored 88 peer-reviewed publications and 30 book chapters. He supervised/co-supervised 27 MSc and PhD students and secured over USD 2.6 Million for funding his research. He served as Visiting Professor at Sichuan University, China (2013-2016), and Anglia Ruskin University, UK (2022-present), and has extensive network and connections with many research active institutions worldwide. Abdelbary’s research area is focused on developing nanomedicine formulations for the treatment of cancer and pulmonary diseases. He is particularly interested in liposomes and proliposome technologies, and how nanoparticle delivery for inhalation is influenced by inhalation device technology. Abdelbary is among the top 2% World Scientists in terms of field citation impact according to Stanford University reports (2019, 2020, 2021, 2022 and 2023).